Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 293, Issue 3, 2007, Pages

  De Lisle, Robert C ^a   Roach, Eileen ^a   Jansson, Kyle ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Small intestinal bacterial overgrowth

Indexed keywords

ACETYLCYSTEINE; LAXATIVE; MUCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL OVERGROWTH; BACTERIUM; CONTROLLED STUDY; CYSTIC FIBROSIS; DIGESTIVE SYSTEM INFLAMMATION; DISULFIDE BOND; DRUG EFFECT; FEEDING; FEMALE; GENE; HISTOLOGY; HYDRATION; INNATE IMMUNITY; INTESTINE CRYPT; LIQUID; MALE; MOUSE; MUCUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SMALL INTESTINE; SOLID; STATISTICAL SIGNIFICANCE;

ACETYLCYSTEINE; ANIMALS; BACTERIA; BODY WEIGHT; CATHARTICS; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; EXPECTORANTS; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; GENE EXPRESSION REGULATION; IMMUNITY, NATURAL; INFLAMMATION; INTESTINE, SMALL; MICE; MICE, INBRED CFTR; MUCUS; POLYETHYLENE GLYCOLS; RNA, BACTERIAL; RNA, RIBOSOMAL, 16S;

EID: 34548799345     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00195.2007     Document Type: Article

References (40)

1. Bali A, Stableforth DE, Asquith P. Prolonged small-intestinal transit time in cystic fibrosis. Br Med J 287: 1011-1013, 1983.
2. Barbara G, Stanghellini V, Brandi G, Cremon C, Di Nardo G, De Giorgio R, Corinaldesi R. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 100: 2560-2568, 2005.
3. Beharry SA, Ackerely C, Corey M, Kent G, Heng YM, Christensen H, Luk C, Yantiss RK, Nasser IA, Zaman M, Freedman SD, Durie PR. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 292: G839-G848, 2006.
4. Bentur L, Hino B, Shamir R, Elias N, Hartman C, Eshach-Adiv O, Berkowitz D. Impaired gastric myolectrical activity in patients with cystic fibrosis. J Cyst Fibros 5: 187-191, 2006.
5. Borowitz D, Durie PR, Clarke LL, Werlin SL, Taylor CJ, Semler J, De Lisle RC, Lewindon PJ, Lichtman SM, Sinaasappel M, Baker RD, Baker SS, Verkade HJ, Lowe ME, Stallings VA, Janghorbani M, Heubi J. Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr 41: 273-285, 2005.
6. Bouquet J, Sinaasappel M, Neijens HJ. Malabsorption in cystic fibrosis: mechanisms and treatment. J Pediatr Gastroenterol Nutr 7, Suppl 1: S30-S35, 1988.
7. Bruzzese E, Raia V, Gaudiello G, Polito G, Buccigrossi V, Formicola V, Guarino A. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther 20: 813-819, 2004.
8. Cantin AM, White TB, Cross CE, Forman HJ, Sokol RJ, Borowitz D. Antioxidants in cystic fibrosis. Conclusions from the CF Antioxidant Workshop, Bethesda, Maryland, November 11-12, 2003. Free Radic Biol Med 42: 15-31, 2007.
9. Clarke LL, Gawenis LR, Bradford EM, Judd LM, Boyle KT, Simpson JE, Shull GE, Tanabe H, Ouellette AJ, Franklin CL, Walker NM. Abnormal Paneth cell granule dissolution and compromised resistance to bacterial colonization in the intestine of CF mice. Am J Physiol Gastrointest Liver Physiol 286: G1050-G1058, 2004.
10. Clarke LL, Gawenis LR, Franklin CL, Harline MC. Increased survival of CFTR knockout mice with an oral osmotic laxative. Lab Anim Sci 46: 612-618, 1996.
11. Cleghorn GJ, Stringer DA, Forstner GG, Durie PR. Treatment of distal intestinal obstruction syndrome in cystic fibrosis with a balanced intestinal lavage solution. Lancet 1: 8-11, 1986.
12. Da Cunha MJ, Summers RW, Thompson HH, Wingate DL, Yanda R. Effects of intestinal secretagogues and distension on small bowel myoelectric activity in fasted and fed conscious dogs. J Physiol 321: 483-494, 1981.
13. Dalzell AM, Freestone NS, Billington D, Heaf DP. Small intestinal permeability and orocaecal transit time in cystic fibrosis. Arch Dis Child 65: 585-588, 1990.
14. De Lisle RC. Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 293: G104-G111, 2007.
15. De Lisle RC, Roach EA, Norkina O. Eradication of small intestinal bacterial overgrowth in the cystic fibrosis mouse reduces mucus accumulation. J Pediatr Gastroenterol Nutr 42: 46-52, 2006.
16. Eckman EA, Cotton CU, Kube DM, Davis PB. Dietary changes improve survival of CFTR S489X homozygous mutant mouse. Am J Physiol Lung Cell Mol Physiol 269: L625-L630, 1995.
17. Emil S, Nguyen T, Sills J, Padilla G. Meconium obstruction in extremely low-birth-weight neonates: guidelines for diagnosis and management. J Pediatr Surg 39: 731-737, 2004.
18. Fridge JL, Conrad C, Gerson L, Castillo RO, Cox K. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr 44: 212-218, 2007.
19. Gregory PC. Gastrointestinal pH, motility/transit and permeability in cystic fibrosis. J Pediatr Gastroenterol Nutr 23: 513-523, 1996.
20. Haston CK, Corey M, Tsui LC. Mapping of genetic factors influencing the weight of cystic fibrosis knockout mice. Mamm Genome 13: 614-618, 2002.
21. Hinojosa-Kurtzberg AM, Johansson MEV, Madsen CS, Hansson GC, Gendler SJ. Novel MUC1 splice variants contribute to mucin overexpression in CFTR-deficient mice. Am J Physiol Gastrointest Liver Physiol 284: G853-G862, 2003.
22. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy 51, Suppl 1: 1-22, 2005.
23. Husebye E, Hellstrom PM, Sundler F, Chen J, Midtvedt T. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 280: G368-G380, 2001.
24. Huynh HQ, Couper RTL, Tran CD, Moore L, Kelso R, Butler RN. N-acetylcysteine, a novel treatment for Helicobacter pylori infection. Dig Dis Sci 49: 1853-1861, 2004.
25. Knowles CH, Martin JE. Slow transit constipation: a model of human gut dysmotility. Review of possible aetiologies. Neurogastroenterol Motil 12: 181-196, 2000.
26. Koletzko S, Corey M, Ellis L, Spino M, Stringer DA, Durie PR. Effects of cisapride in patients with cystic fibrosis and distal intestinal obstruction syndrome. J Pediatr 117: 815-822, 1990.
27. Lewindon PJ, Robb TA, Moore DJ, Davidson GP, Martin AJ. Bowel dysfunction in cystic fibrosis: importance of breath testing. J Paediatr Child Health 34: 79-82, 1998.
28. Liu W, Saint DA. A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. Anal Biochem 302: 52-59, 2002.
29. Malmberg EK, Noaksson KA, Phillipson M, Johansson ME, Hinojosa-Kurtzberg M, Holm L, Gendler SJ, Hansson GC. Increased levels of mucins in the cystic fibrosis mouse small intestine and modulator effects of the Muc1 mucin expression. Am J Physiol Gastrointest Liver Physiol 291: G203-G210, 2006.
30. Mascarenhas MR, Mondick JT, Barrett JS, Zhuang H, Edwards K, Schall JI. Comparison of gastric emptying and small bowel transit in subjects with CF and healthy controls (Abstract). Pediatr Pulmonol Suppl 29: 377, 2006.
31. Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology 148: 257-266, 2002.
32. Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 72: 6040-6049, 2004.
33. Norkina O, Kaur S, Ziemer D, De Lisle RC. Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 286: G1032-G1041, 2004.
34. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 130: S78-S90, 2006.
35. + absorption across human nasal epithelial cells. J Cell Physiol 201: 106-116, 2004.
36. Sonnenburg JL, Angenent LT, Gordon JI. Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? Nat Immun 5: 569-573, 2004.
37. Sun F, Tai S, Lim T, Baumann U, King M. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum. Can Respir J 9: 401-406, 2002.
38. Thomsson KA, Hinojosa-Kurtzberg M, Axelsson KA, Domino SE, Lowe JB, Gendler SJ, Hansson GC. Intestinal mucins from cystic fibrosis mice show increased fucosylation due to an induced fucalpha1-2 glycosyltransferase. Biochem J 367: 609-616, 2002.
39. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 103: 4628-4633, 2006.
40. Wesley A, Forstner J, Qureshi R, Mantle M, Forstner G. Human intestinal mucin in cystic fibrosis. Pediatr Res 17: 65-69, 1983.